Arontier

Arontier is an AI-driven drug discovery company. Its Hybrid AI integrates the fundamental principles of physics with advanced AI to design proteins, antibodies, peptides, and small molecules with atomic precision. The company states that its approach fuses physics-based energy functions with graph neural networks, providing predictive power even when experimental data is scarce. It offers end-to-end drug discovery services spanning biologics design, small molecule discovery, and the AD3 Platform, a SaaS platform with 5 modules and 21 applications.

Arontier presents itself as an AI-driven drug discovery partner. Its stated mission is to reach drug discovery answers faster and more precisely through AI-based design, reinterpreting accumulated experimental data to design target-specific candidates de novo. The company describes a journey including a "Structure-Based AI Discovery of Small-Molecule Drug Candidates" project associated with MSIT.

Physics-informed AI for atomic-level drug discovery, aiming to help partners reach success with fewer experiments and higher probability.

• AD3 Platform

  SaaS platform with 5 modules and 21 applications; an integrated AI + physics-based platform enabling atomic-level understanding and optimization.

• Biologics Design

  Structure-guided design for antibodies, peptides, and proteins, delivering experimentally validated hits with minimal wet-lab burden; includes Antibody Discovery (De Novo), Peptide Design, Protein Nanoparticle Platform, and Synthetic Antigen Design.

• Small Molecule Discovery

  AI-powered large-scale virtual screening of 100M compounds in 72 hours, reverse target screening across 18,000+ proteins, and integrated in silico ADMET profiling with 30+ AI models.

1. 1Arontier — AI-Driven Drug Discoveryarontier.co
2. 2About – Arontierarontier.co
3. 3Services – Arontierarontier.co